Canadian Urological Association guideline on the management of non-muscle-invasive bladder cancer - Full-text.
作者信息
Bhindi Bimal, Kool Ronald, Kulkarni Girish S, Siemens D Robert, Aprikian Armen G, Breau Rodney H, Brimo Fadi, Fairey Adrian, French Christopher, Hanna Nawar, Izawa Jonathan I, Lacombe Louis, McPherson Victor, Rendon Ricardo A, Shayegan Bobby, So Alan I, Zlotta Alexandre R, Black Peter C, Kassouf Wassim
机构信息
Section of Urology, Department of Surgery, University of Calgary, Calgary, AB, Canada.
Division of Urology, Department of Surgery, McGill University Health Centre, Montreal, QC, Canada.
出版信息
Can Urol Assoc J. 2021 Aug;15(8):E424-E460. doi: 10.5489/cuaj.7367.
Abstract
摘要
相似文献
1
Canadian Urological Association guideline on the management of non-muscle-invasive bladder cancer - Full-text.加拿大泌尿外科协会非肌层浸润性膀胱癌管理指南 - 全文
Can Urol Assoc J. 2021 Aug;15(8):E424-E460. doi: 10.5489/cuaj.7367.
2
Canadian Urological Association guideline on the management of non-muscle-invasive bladder cancer - Abridged version.加拿大泌尿外科协会非肌层浸润性膀胱癌管理指南 - 简版
Can Urol Assoc J. 2021 Aug;15(8):230-239. doi: 10.5489/cuaj.7487.
3
Canadian Urological Association guideline: Muscle-invasive bladder cancer.加拿大泌尿外科协会指南：肌层浸润性膀胱癌
Can Urol Assoc J. 2019 Aug;13(8):230-238. doi: 10.5489/cuaj.5902.
4
2022 UPDATE: Canadian Urological Association-Canadian Urologic Oncology Group guideline: Metastatic castration-naive and castration-sensitive prostate cancer Full-text.2022年更新：加拿大泌尿外科学会-加拿大泌尿肿瘤学组指南：转移性去势初治和去势敏感性前列腺癌全文
Can Urol Assoc J. 2022 Dec;16(12):E581-E589. doi: 10.5489/cuaj.8148.
5
Canadian Urological Association guideline: Management of ureteral calculi - Full-text.加拿大泌尿外科协会指南：输尿管结石的管理 - 全文
Can Urol Assoc J. 2021 Dec;15(12):E676-E690. doi: 10.5489/cuaj.7581.
6
Canadian Urological Association guideline: Management of small renal masses - Full-text.加拿大泌尿外科协会指南：小肾肿块的管理 - 全文
Can Urol Assoc J. 2022 Feb;16(2):E61-E75. doi: 10.5489/cuaj.7763.
7
Canadian Urological Association guideline: Diagnosis, management, and surveillance of neurogenic lower urinary tract dysfunction - Full text.加拿大泌尿外科协会指南：神经源性下尿路功能障碍的诊断、管理及监测——全文
Can Urol Assoc J. 2019 Jun;13(6):E157-E176. doi: 10.5489/cuaj.5912.
8
Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline.非转移性肌肉浸润性膀胱癌治疗：AUA/ASCO/ASTRO/SUO 指南。
J Urol. 2017 Sep;198(3):552-559. doi: 10.1016/j.juro.2017.04.086. Epub 2017 Apr 26.
9
Non-muscle-invasive Bladder Cancer: Side-by-Side Guideline Comparison.非肌肉浸润性膀胱癌：指南并排比较。
Eur Urol Focus. 2023 Nov;9(6):954-956. doi: 10.1016/j.euf.2023.05.004. Epub 2023 Jun 10.
10
Guideline of guidelines: non-muscle-invasive bladder cancer.指南之指南：非肌层浸润性膀胱癌
BJU Int. 2017 Mar;119(3):371-380. doi: 10.1111/bju.13760. Epub 2017 Jan 24.
引用本文的文献
1
Impact of concomitant carcinoma in situ distribution on non-muscle-invasive bladder cancer progression risk.原位癌分布情况对非肌层浸润性膀胱癌进展风险的影响。
BJU Int. 2025 Aug;136(2):236-244. doi: 10.1111/bju.16793. Epub 2025 May 26.
2
Assessing the methodologic heterogeneity of Canadian Urological Association guidelines Adoption of the GRADE approach (2018-2023).评估加拿大泌尿外科学会指南采用GRADE方法（2018 - 2023年）的方法学异质性。
Can Urol Assoc J. 2025 Jun;19(6):173-180. doi: 10.5489/cuaj.8926.
3
Adherence to First-Line Intravesical Bacillus Calmette-Guérin Therapy in the Context of Guideline Recommendations for US Patients With High-Risk Non-muscle Invasive Bladder Cancer.在美国高危非肌层浸润性膀胱癌患者的指南建议背景下，一线膀胱内卡介苗治疗的依从性。
J Health Econ Outcomes Res. 2024 Oct 28;11(2):109-117. doi: 10.36469/001c.124208. eCollection 2024.
4
Pharmacological Inhibition of Endogenous Hydrogen Sulfide Production Slows Bladder Cancer Progression in an Intravesical Murine Model.内源性硫化氢生成的药理学抑制减缓膀胱内小鼠模型中膀胱癌的进展。
Pharmaceuticals (Basel). 2024 Sep 14;17(9):1212. doi: 10.3390/ph17091212.
5
Post-marketing drug safety surveillance of enfortumab vedotin: an observational pharmacovigilance study based on a real-world database.恩福妥滨上市后药物安全性监测：基于真实世界数据库的观察性药物警戒研究。
Front Immunol. 2024 Aug 20;15:1397692. doi: 10.3389/fimmu.2024.1397692. eCollection 2024.
6
A Real-World Retrospective Analysis of the Management of Advanced Urothelial Carcinoma in Canada.加拿大晚期尿路上皮癌的真实世界回顾性分析。
Curr Oncol. 2024 Jan 25;31(2):704-722. doi: 10.3390/curroncol31020052.
7
Is switching intravesical chemotherapeutic agents beneficial in short-term recurrent high-risk non-muscle-invasive bladder tumors? A 5-year retrospective study.短期复发的高危非肌肉浸润性膀胱肿瘤中更换膀胱内化疗药物是否有益？一项 5 年回顾性研究。
BMC Urol. 2024 Jan 31;24(1):25. doi: 10.1186/s12894-024-01410-1.
8
Carcinoma In Situ (CIS): Is There a Difference in Efficacy between Various BCG Strains? A Comprehensive Review of the Literature.原位癌（CIS）：不同卡介苗菌株之间的疗效是否存在差异？文献综述
Cancers (Basel). 2024 Jan 5;16(2):245. doi: 10.3390/cancers16020245.
9
Salvage therapy for BCG failure with intravesical sequential gemcitabine and docetaxel in patients with recurrent NMIBC.复发性非肌层浸润性膀胱癌患者卡介苗治疗失败后采用吉西他滨和多西他赛膀胱内序贯挽救治疗。
Can Urol Assoc J. 2024 Feb;18(2):33-40. doi: 10.5489/cuaj.8341.
10
Existing trends and applications of artificial intelligence in urothelial cancer A scoping review.人工智能在尿路上皮癌中的现有趋势与应用：一项范围综述
Can Urol Assoc J. 2023 Nov;17(11):E395-E401. doi: 10.5489/cuaj.8322.
本文引用的文献
1
Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study.帕博利珠单抗单药治疗卡介苗（BCG）无应答的高风险非肌肉浸润性膀胱癌（KEYNOTE-057）：一项开放标签、单臂、多中心、2 期研究。
Lancet Oncol. 2021 Jul;22(7):919-930. doi: 10.1016/S1470-2045(21)00147-9. Epub 2021 May 26.
2
European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel.欧洲泌尿外科学会（EAU）非肌肉浸润性膀胱癌（NMIBC）预后因素风险组，纳入世界卫生组织 2004/2016 年和世界卫生组织 1973 年分级系统：EAU NMIBC 指南小组的更新。
Eur Urol. 2021 Apr;79(4):480-488. doi: 10.1016/j.eururo.2020.12.033. Epub 2021 Jan 6.
3
Holmium Laser En-bloc Resection Versus Conventional Transurethral Resection of Bladder Tumors for Treatment of Non-muscle-invasive Bladder Cancer: A Randomized Clinical Trial.钬激光整块切除术与传统经尿道膀胱肿瘤切除术治疗非肌层浸润性膀胱癌的随机临床试验。
Eur Urol Focus. 2021 Sep;7(5):1035-1043. doi: 10.1016/j.euf.2020.12.003. Epub 2020 Dec 30.
4
Radical Cystectomy Against Intravesical BCG for High-Risk High-Grade Nonmuscle Invasive Bladder Cancer: Results From the Randomized Controlled BRAVO-Feasibility Study.根治性膀胱切除术联合膀胱内卡介苗治疗高危高级别非肌肉浸润性膀胱癌：随机对照 BRAVO-可行性研究结果。
J Clin Oncol. 2021 Jan 20;39(3):202-214. doi: 10.1200/JCO.20.01665. Epub 2020 Dec 17.
5
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial.纳武拉非尼基因导管治疗卡介苗无应答性非肌肉浸润性膀胱癌：一项单臂、开放标签、重复剂量临床试验。
Lancet Oncol. 2021 Jan;22(1):107-117. doi: 10.1016/S1470-2045(20)30540-4. Epub 2020 Nov 27.
6
Feasibility and accuracy of pathological diagnosis in en-bloc transurethral resection specimens versus conventional transurethral resection specimens of bladder tumour: evaluation with pT1 substaging by 10 pathologists.整块经尿道切除标本与传统经尿道切除标本在膀胱肿瘤病理诊断中的可行性和准确性：10 位病理学家评估 pT1 亚分期的效果。
Histopathology. 2021 Jun;78(7):943-950. doi: 10.1111/his.14307. Epub 2021 Mar 26.
7
Impact of second transurethral resection on recurrence in patients with high-grade Ta bladder cancer.二次经尿道电切术对高级别 Ta 膀胱癌患者复发的影响。
Int J Urol. 2020 Dec;27(12):1130-1135. doi: 10.1111/iju.14372. Epub 2020 Sep 28.
8
Sex Differences in Bladder Cancer Immunobiology and Outcomes: A Collaborative Review with Implications for Treatment.膀胱癌免疫生物学和结局的性别差异：具有治疗意义的协作性综述
Eur Urol Oncol. 2020 Oct;3(5):622-630. doi: 10.1016/j.euo.2020.08.013. Epub 2020 Sep 20.
9
Assessing the Impact of the Absence of Detrusor Muscle in Ta Low-grade Urothelial Carcinoma of the Bladder on Recurrence-free Survival.评估膀胱 Ta 低级别尿路上皮癌中逼尿肌缺失对无复发生存率的影响。
Eur Urol Focus. 2021 Nov;7(6):1324-1331. doi: 10.1016/j.euf.2020.08.007. Epub 2020 Sep 6.
10
Primary Ta high grade bladder tumors: Determination of the risk of progression.原发性高级别膀胱肿瘤：进展风险的确定。
Urol Oncol. 2021 Feb;39(2):132.e7-132.e11. doi: 10.1016/j.urolonc.2020.07.017. Epub 2020 Aug 7.
Zotero 插件